Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment

Marcus Maurer, Werner Aberer, Laurence Bouillet, Teresa Caballero, Vincent Fabien, Gisèle Kanny, Allen Kaplan, Hilary Longhurst, Andrea Zanichelli and on behalf of I O S Investigators

PLOS ONE, 2013, vol. 8, issue 2, 1-7

Abstract: Background: Attacks of hereditary angioedema (HAE) are unpredictable and, if affecting the upper airway, can be lethal. Icatibant is used for physician- or patient self-administered symptomatic treatment of HAE attacks in adults. Its mode of action includes disruption of the bradykinin pathway via blockade of the bradykinin B2 receptor. Early treatment is believed to shorten attack duration and prevent severe outcomes; however, evidence to support these benefits is lacking. Objective: To examine the impact of timing of icatibant administration on the duration and resolution of HAE type I and II attacks. Methods: The Icatibant Outcome Survey is an international, prospective, observational study for patients treated with icatibant. Data on timings and outcomes of icatibant treatment for HAE attacks were collected between July 2009–February 2012. A mixed-model of repeated measures was performed for 426 attacks in 136 HAE type I and II patients. Results: Attack duration was significantly shorter in patients treated

Date: 2013
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053773 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 53773&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0053773

DOI: 10.1371/journal.pone.0053773

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().